Brought to you by 
Qiagen offers to buy Cellestis for $355mm, later ups offer
Apr 2011
Executive Summary
Molecular diagnostics company Qiagen NV is proposing to buy public Australian diagnostics firm Cellestis Ltd. for A$341mm ($355mm) in cash, or $3.69 per share (a 25% premium).
Deal Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Qiagen offers to buy Cellestis for $355mm, later ups offer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice